RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-13.46%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$627M
AUM Growth
+$627M
(-11%)
Cap. Flow
+$21.3M
Cap. Flow
% of AUM
3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.67%
Holding
102
New
6
Increased
38
Reduced
34
Closed
9
Top Buys
| 1 |
Humana
HUM
|
$14.3M |
| 2 |
Cigna
CI
|
$14.3M |
| 3 |
Pfizer
PFE
|
$13.2M |
| 4 |
McKesson
MCK
|
$9.62M |
| 5 |
AET
Aetna Inc
AET
|
$9.52M |
Top Sells
| 1 |
Biogen
BIIB
|
$20.3M |
| 2 |
Johnson & Johnson
JNJ
|
$18.6M |
| 3 |
UnitedHealth
UNH
|
$9.74M |
| 4 |
CVS Health
CVS
|
$8.39M |
| 5 |
Merck
MRK
|
$7.9M |
Sector Composition
| 1 | Healthcare | 91.99% |
| 2 | Financials | 2.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Merck
MRK
$210B
| $4.94M | 0.79% |
100,000
-160,000
| -62% | -$7.9M |
|
52
Cooper Companies
COO
$13.3B
| $4.91M | 0.78% |
33,000
-8,000
| -20% | -$1.19M |
|
|
MDVN
53
DELISTED
MEDIVATION, INC.
MDVN
| $4.85M | 0.77% |
114,000
+68,000
| +148% | +$935K |
|
|
HTWR
54
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $4.55M | 0.73% |
87,000
+71,300
| +454% | +$3.73M |
|
|
RVNC
55
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.4M | 0.7% |
148,000
-24,000
| -14% | -$714K |
|
|
RAD
56
DELISTED
Rite Aid Corporation
RAD
| $4.04M | 0.64% |
665,000
-1,152,000
| -63% | -$6.99M |
|
57
Viatris
VTRS
$12.3B
| $4.03M | 0.64% |
100,000
+17,000
| +20% | +$684K |
|
|
CLVS
58
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.95M | 0.63% |
43,000
-17,765
| -29% | -$1.63M |
|
59
Iovance Biotherapeutics
IOVA
$800M
| $3.94M | 0.63% |
683,108
+127,108
| +23% | +$732K |
|
|
CYBX
60
DELISTED
CYBERONICS INC
CYBX
| $3.46M | 0.55% |
57,000
-43,000
| -43% | -$2.61M |
|
61
Ionis Pharmaceuticals
IONS
$9.64B
| $3.23M | 0.52% |
80,000
-14,000
| -15% | -$566K |
|
|
KITE
62
DELISTED
Kite Pharma, Inc.
KITE
| $3.17M | 0.51% |
57,000
-9,000
| -14% | -$501K |
|
63
Celldex Therapeutics
CLDX
$1.57B
| $3.11M | 0.5% |
295,000
+98,000
| +50% | +$1.03M |
|
|
PTLA
64
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.03M | 0.48% |
71,000
-5,000
| -7% | -$213K |
|
65
Insulet
PODD
$24.2B
| $2.85M | 0.45% |
110,000
+20,000
| +22% | +$518K |
|
|
ELGX
66
DELISTED
Endologix Inc
ELGX
| $2.81M | 0.45% |
229,000
+50,000
| +28% | +$613K |
|
|
ARIA
67
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $2.51M | 0.4% |
430,000
-20,000
| -4% | -$117K |
|
|
OREX
68
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $2.51M | 0.4% |
1,189,000
+400,000
| +51% | +$844K |
|
69
Astria Therapeutics
ATXS
$394M
| $2.43M | 0.39% |
300,427
+35,000
| +13% | +$283K |
|
70
Esperion Therapeutics
ESPR
$490M
| $2.36M | 0.38% |
100,000
-12,000
| -11% | -$283K |
|
71
MacroGenics
MGNX
$121M
| $2.31M | 0.37% |
107,959
| – | – |
|
72
Halozyme
HALO
$8.75B
| $2.31M | 0.37% |
172,000
| – | – |
|
|
CPHD
73
DELISTED
Cepheid Inc
CPHD
| $2.31M | 0.37% |
51,000
| – | – |
|
74
Omnicell
OMCL
$1.51B
| $2.3M | 0.37% |
74,000
| – | – |
|
75
Rigel Pharmaceuticals
RIGL
$710M
| $2.29M | 0.36% |
925,000
| – | – |
|